High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
These stocks have been struggling lately, but they could be underrated buys in the long run.
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car
The approval extends semaglutide beyond obesity, but Novo disclosed neither launch timing nor incremental revenue.
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
You might regret ignoring these companies at current levels.
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.
They are way more than just GLP-1 stocks.
WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.
West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.
Novo Nordisk is playing catch-up in the GLP-1 race.
Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and diabetes...
The S&P 500 and Dow Jones hit highs while the Nasdaq raced above key levels as oil prices and yields fell. Palantir, Cloudflare and SpaceX were big movers amid earings.
Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.
Key takeawaysEli Lilly’s second-quarter revenue surged 48 per cent to US$22. 97 billion, beating Wall Street expectations by more than US$2 billion.
Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.
Novo Nordisk beats Q2 earnings and sales estimates as GLP-1 demand grows, but pricing pressure, outlook concerns and pipeline setbacks sent shares lower.
Eli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back of...
Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.
Aug 5 () - Eli Lilly and Co raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs. The move comes less than a day after rival Novo Nordisk also hiked its full-year profit and sales forecast, banking on its oral Wegovy pill to help claw back lost ground from Lilly in the lucrative obesity market.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.